{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:19:07Z","timestamp":1772090347009,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejps.2021.106032","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T08:22:07Z","timestamp":1633335727000},"page":"106032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats"],"prefix":"10.1016","volume":"168","author":[{"given":"Hans","family":"Helleberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke Hvid","family":"Lindecrona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Thygesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Bjelke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.106032_bib0001","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.ejps.2021.106032_bib0002","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejps.2021.106032_bib0003","series-title":"Metabolite Safety in Drug Development","first-page":"45","article-title":"Metabolite technology: qualitative and quantitative","author":"Dear","year":"2016"},{"key":"10.1016\/j.ejps.2021.106032_bib0004","first-page":"3990","article-title":"Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society","volume":"85","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.106032_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106030","article-title":"Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects","author":"Helleberg","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106032_bib0006","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","volume":"157","author":"Ho","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejps.2021.106032_bib0007","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2009. Guideline on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2)."},{"key":"10.1016\/j.ejps.2021.106032_bib0008","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-17-1073","article-title":"Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejps.2021.106032_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgaa049","article-title":"Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial","volume":"105","author":"Johannsson","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.106032_bib0010","unstructured":"Novo Nordisk A\/S, 2021. Sogroya 10mg\/1.5mL solution for injection in pre-filled pen summary of product characteristics."},{"key":"10.1016\/j.ejps.2021.106032_bib0011","unstructured":"Novo Nordisk Inc, 2020. Sogroya, somapacitan-beco injection prescribing information."},{"key":"10.1016\/j.ejps.2021.106032_bib0012","unstructured":"Novo Nordisk Pharma Ltd, 2021. Sogroya, somapacitan-beco injection prescribing Information."},{"key":"10.1016\/j.ejps.2021.106032_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/cen.14273","article-title":"Similar safety and efficacy in previously treated adults with growth hormone deficiency randomised to once-weekly somapacitan or daily growth hormone","author":"Otsuka","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejps.2021.106032_bib0014","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1021\/acs.bioconjchem.8b00463","article-title":"Long-acting human growth hormone analogue by noncovalent albumin binding","volume":"29","author":"Ramirez-Andersen","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2021.106032_bib0015","doi-asserted-by":"crossref","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","article-title":"A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile","volume":"99","author":"Rasmussen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.106032_bib0016","doi-asserted-by":"crossref","first-page":"e1847","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-weekly somapacitan versus daily GH in children with GH deficiency: results from a randomized phase 2 trial","volume":"105","author":"Savendahl","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.106032_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ghir.2017.05.006","article-title":"Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: a reversible non-covalent albumin-binding growth hormone","volume":"35","author":"Thygesen","year":"2017","journal-title":"Growth. Horm. IGF. Res."},{"key":"10.1016\/j.ejps.2021.106032_bib0018","series-title":"Safety Testing of Drug Metabolites: Guidance for Industry","year":"2016"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:59:34Z","timestamp":1760529574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721003353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":18,"alternative-id":["S0928098721003353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106032","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106032"}}